Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Symposium

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on May 14, 2021 1:03pm

104 Views

Post# 33204109

RE:RE:Symposium

The difference between me and you is the fact you see success in running a business solely as success in running the trials.
I see the success in running the business as a result of success in running all parts of it, including cost control, strategic planning, marketing, sales and competent leadership among others.

qwerty22 wrote:
It's clinical, at a clinical conference. They are talking to the people that prescribe the drug. This is about clinical engagement and sales not what you want it to be. Let them run their business.

About ACTHIV

The American Conference for the Treatment of HIV (ACTHIV) is the premier conference in the US dedicated exclusively to the frontline care team and its members who are caring for persons living with or at risk of acquiring HIV. The conference delivers information on new developments and research findings that can be rapidly translated and directly applied to the clinical setting.

scarlet1967 wrote:

I think the purpose of it is to discuss both lipodystrophy and NASH. Would it be wonderful to get some KOLs together and arrange for a conference on a well followed platform to discuss their programs. They are trying to bring awareness to their science but the net effect would be much higher if it was targeting bigger audience.
https://www.linkedin.com/posts/theratechnologies-inc_symposium-acthiv-acthiv2021-activity-6798957933863538688-99CH